5至11岁儿童接种BNT162b2新冠疫苗后的混合免疫
本研究为多机构前瞻性纵向队列研究,纳入加拿大渥太华5-11岁儿童,比较有或无SARS-CoV-2感染史者接种BNT162b2后的刺突IgG抗体水平;感染康复儿童在第一剂和第二剂后抗体水平均显著更高,多数在第一剂后2-3周达饱和,第二剂未改变饱和水平;作者认为单剂对康复儿童可能等效或优于未感染儿童的两剂基础免疫,需进一步研究单剂持久性与质量。
要点
- 感染康复儿童接种第一剂后刺突IgG显著高于未感染儿童(p<0.001),第二剂后仍显著(p=0.01)。
- 多数康复儿童在第一剂后2-3周达抗体饱和,第二剂未改变饱和水平。
- 作者认为康复儿童单剂可能等效或优于未感染儿童两剂基础免疫,需进一步研究单剂持久性与质量。
核心结论
- 5-11岁SARS-CoV-2感染康复儿童接种第一剂BNT162b2后抗体水平高于未感染儿童;多数在第一剂后2-3周达抗体饱和,第二剂未改变饱和水平;作者认为单剂对康复儿童可能等效或优于未感染儿童的两剂基础免疫,需进一步研究单剂持久性与质量。
研究设计与样本
- 多机构、纵向、前瞻性队列研究;儿童来自2020年9月至2021年3月渥太华(Ontario)一项病例确认抗体监测研究,至少一名家庭成员SARS-CoV-2 RT-PCR阳性;2021年11月至2022年4月邀请计划接种两剂BNT162b2的5-11岁儿童参与。
- 153名合格儿童中75名完成随访,中位年龄8.9岁(IQR 7.4-10.2),女性38名(50.7%),白人59名(78.7%)。
- 主要暴露为既往SARS-CoV-2感染(RT-PCR阳性或SARS-CoV-2抗N IgG抗体存在);主要结局为第一剂后2-3周和第二剂后3-4周测定的刺突IgG抗体水平。
主要发现
- 75名完成随访儿童中54名(72%)有既往SARS-CoV-2感染。
- SARS-CoV-2康复儿童接种第一剂后刺突IgG抗体水平显著高于未感染儿童(p<0.001)。
- SARS-CoV-2康复儿童接种第二剂后刺突IgG抗体水平显著高于未感染儿童(p=0.01)。
- 多数康复儿童在第一剂后2-3周达抗体饱和,第二剂未改变饱和水平。
临床怎么用
- 作者认为SARS-CoV-2康复儿童单剂疫苗可能等效或优于未感染儿童的两剂基础免疫系列。
- 作者指出需进一步研究该人群单剂疫苗的持久性和质量。
局限性
- 原文未报告局限性;作者在结论中提出需进一步研究单剂疫苗在该人群中的持久性和质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The immune response to coronavirus disease 2019 (COVID-19) vaccination is stronger among adults with prior infection (hybrid immunity). It is important to understand if children demonstrate a similar response to better inform vaccination strategies. Our study investigated the humoral response after BNT162b2 COVID-19 vaccine doses in SARS-CoV-2 naïve and recovered children (5-11 years). METHODS: A multi-institutional, longitudinal, prospective cohort study was conducted. Children were enrolled in a case-ascertained antibody surveillance study in Ottawa, Ontario from September/2020-March/2021; at least one household member was severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) positive on RT-PCR. In November 2021, BNT162b2 COVID-19 vaccine was authorized for children aged 5-11 in Canada. Children enrolled in the surveillance study intending to receive two vaccine doses were invited to participate in this study from November 2021-April 2022. Main exposure was prior SARS-CoV-2 infection, defined by positive RT-PCR or SARS-CoV-2 anti-N IgG antibody presence. Primary outcome was spike IgG antibody levels measured following the first vaccine dose (2-3 weeks) and second vaccine dose (3-4 weeks). RESULTS: Of the 153 eligible children, 75 participants (median age 8.9 IQR (7.4, 10.2) years; 38 (50.7 %) female; 59 (78.7 %) Caucasian) had complete follow-up. Fifty-four (72 %) children had prior SARS-COV-2 infection. Spike IgG antibody levels are significantly higher in SARS-CoV-2 recovered participants after receiving the first dose (p < 0.001) and the second (p = 0.01) compared to infection naïve children. CONCLUSIONS AND RELEVANCE: SARS-CoV-2 recovered children (5-11 years) demonstrated higher antibody levels following first BNT162b2 vaccine dose compared with naïve children. Most reached antibody saturation two to three weeks after the first dose; a second dose didn't change the saturation level. A single vaccine dose in SARS-CoV-2 recovered children may be equivalent or superior to a 2-dose primary series in naïve children. Further research is needed on the durability and quality of a single vaccine dose in this population.
引用
- Tsampalieros A, Zemek R, Barrowman N, et al. Hybrid immunity after BNT162b2 Covid-19 vaccine administration in children aged 5 to 11 years. Vaccine. 2024. PMID: 38789373. doi:10.1016/j.vaccine.2024.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。